Press releases
- Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
- Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
- Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
- Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
- Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
- Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
- Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
More ▼
Key statistics
On Friday, Sangamo Therapeutics Inc (0R1D:LSE) closed at 0.5355, 84.66% above the 52 week low of 0.29 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.5355 |
Average volume | 9.52k |
---|---|
Shares outstanding | 207.50m |
Free float | 191.50m |
P/E (TTM) | -- |
Market cap | 115.33m USD |
EPS (TTM) | -1.46 USD |
Data delayed at least 20 minutes, as of May 03 2024 18:57 BST.
More ▼